JP Morgan Week 2025 – Catherine Owen Adams
The last few years at JP Morgan there’s been a consensus that the neurological disease space is one to watch, as new treatments have changed the game in conditions like Alzheimer’s and Parkinson’s.
At this year’s conference, pharmaphorum editor-in-chief Jonah Comstock caught up with Catherine Owen Adams, the CEO of Acadia Pharmaceuticals, to talk about her company’s offerings, including Nuplazid, the only approved medication for treating the hallucinations and delusions associated with Parkinson’s disease.
They discuss why it’s so important to treat these symptoms and to raise public awareness of them as well. Adams also talks about her company's expansion into rare disease and other areas, as well as additional neurological conditions.
Check out the full interview below, which also gets into the shifting political winds in the United States and the industry’s hopes for IRA reform.
